Capital Mãe

计划入组 446 人

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

计划入组 369 人 · 首次发布于 2022 年 7 月 27 日

CAPITAL OFFLOAD-SHOCK

计划入组 456 人 · 首次发布于 2026 年 8 月 11 日

TCB-004

TCB-007

TCB-2

Hercules Capital

United States

Rand Capital

Associated Capital

United States

Clairity Secures $43M Series B to Commercialize First FDA-Authorized AI Platform for Breast Cancer Risk Prediction

Danforth Advisors Acquires PharmaDirections to Create Comprehensive Drug Development Platform

Trinity Biotech Secures $7.0 Million Investment from Perceptive Advisors and Regains Nasdaq Compliance